Clinical trial
U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne
NCT01706263 is registered in ClinicalTrials.gov with Stiefel, a GSK Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne
- Lead sponsor
- Stiefel, a GSK Company
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 1, 2009
- Completion date
- November 20, 2009
- Enrollment
- 28 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.